EGFR and non-small cell lung carcinoma: Recently, amivantamab and mobocertinib received Breakthrough Therapy Designations from the US FDA for the treatment of patients with metastatic NSCLC with EGFR Exon 20ins, whose disease has progressed on or after platinum‐based chemotherapy.4, 5, 6